CDK4 and neoplasm: Consistent with several reports that the TME can drive therapeutic resistance and disease progression even in TNBC, tumour–stroma interactions have been shown to modulate the sensitivity of TNBC cells to diverse drugs, including CDK4/6 inhibitors [27, 210].